Arovella Therapeutics (ASX:ALA) Short-Term Capital Lease Obligation : A$0.00 Mil (As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics Short-Term Capital Lease Obligation?

Arovella Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.00 Mil.

Arovella Therapeutics's annual Short-Term Capital Lease Obligation declined from Jun. 2022 (A$0.07 Mil) to Jun. 2023 (A$0.00 Mil) but then stayed the same from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.00 Mil).

Arovella Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Arovella Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Short-Term Capital Lease Obligation Chart

Arovella Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.08

0.07

Arovella Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.07	-	-	-	-

Arovella Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Arovella Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

E4NA:Germany

Address

84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.arovella.com

Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Arovella Therapeutics Headlines

No Headlines